Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Taking on Solid Tumors - 1: Japan Sees Rush of Bispecific Approvals with Good Progress in Blood Cancers, and More
Japan has been enjoying a string of approvals for bispecific antibodies particularly over the past year. Companies are now going after new bispecific targets and indications and even trispecific drugs, and while these technologies have thrived mostly in blood cancers,…
To read the full story
Related Article
- Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
July 18, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- Taking on Solid Tumors - 7: Astellas Aims for Global Lead in CLDN18.2 TCEs, Building on Success with Vyloy
July 3, 2025
- Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
- Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
ACADEMIA
- NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…